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INTRODUCTION:  Emphysema  is  a  leading  cause  of  disability  and  death.  Patients  who  require  ventilator
support  as  a  result  of  respiratory  failure  have  limited  treatment  options.  We  report  a  successful  outcome
for a  ventilator  dependent  patient  in whom  endobronchial  valves  were  inserted  into  lobes  assessed  as
being without  collateral  ventilation.
PRESENTATION  OF  CASE:  A  54  year  old  male  patient  had  been  ventilator  dependent  for  two  months  due
to  respiratory  insufﬁciency  from  emphysema.  Prior  to admission,  FEV1 was  0.89L  (25%  predicted)  and
RV was  4.5L  (205%  predicted).  CT scan showed  destruction  of right  lower  and  middle  lobes  and  left
lower  lobe.  Chartis  assessment  showed  the  absence  of  collateral  ventilation.  Zephyr  endobronchial  valves
were placed  in left and right lower  lobes.  Lung  volume  reduction  bilaterally  was  conﬁrmed  on chest  X-
ray and  CT  scan  the following  day.  On  day  three,  ventilator  support  was  discontinued  and  there  was
no  requirement  for  supplementary  oxygen.  At  30  days  post  procedure,  the RV  reduced  to  3.2L  (142%
predicted)  and  the  FEV1 increased  to  1.32L  (38%  predicted).
DISCUSSION:  Hyperinﬂation  in  emphysema  compromises  lung  function.  For  this  ventilator  dependent
patient,  there  were  no  other  treatment  options.  Endoscopic  lung  volume  reduction  was  successfully
achieved  by  bilateral  lower  lobe  placement  of  Zephyr  endobronchial  valves  with  a prior  assessment
using  Chartis  to determine  the  absence  of  collateral  ﬂow  in the  targeted  lobes.  The  patient  achieved  an
impressive  48%  improvement  in FEV1 and  a 29%  reduction  in  RV.
CONCLUSION:  Endoscopic  lung  volume  reduction  assisted  by Chartis  to  plan  treatment  resulted  in  a  clinical
eneﬁt
gical and  a  health-economic  b
© 2011 Sur
. Introduction
Emphysema is a leading cause of disability and death. Patients
ho require ventilator support as a result of respiratory failure have
imited treatment options. We  report a successful outcome for a
entilator dependant patient in whom endobronchial valves were
nserted into lobes assessed as being without collateral ventilation.
. Presentation of case
A 54 year old male patient had been in the Intensive Care Unit
n a ventilator for a period of two months as a result of respiratory
nsufﬁciency due to emphysema. Due to the prolonged ventila-
ion, he had a tracheostomy. He was transferred to our unit for
he bronchoscopic insertion of endobronchial valves with the aim
f reducing hyperinﬂation and improving respiratory function.
He had a 20 year history of Chronic Obstructive Pulmonary Dis-
ase. Seven years prior to admission he had ceased smoking and
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2 years later had been medically retired from his occupation as a
driver.
Three months prior to his admission to the Intensive Care Unit
he was  oxygen dependent and had an FEV1 of 0.89L (25% predicted),
RV of 4.5L (205% predicted). A CT scan whilst on the ICU showed
signiﬁcant destruction of the right lower and middle lobes and left
lower lobe (Fig. 1). Screening for alpha-1-antitrypsin deﬁciency was
negative.
Based upon the CT scan which showed extensive disease in the
lower lobes bilaterally, both lower lobes were determined to be
target lobes for endo-bronchial valves (EBV). In order to assess the
degree of collateral ventilation, under low pressure ventilation, a
Chartis® balloon catheter was inserted through the tracheostomy
and inserted into the left upper lobe. The lobe was then obstructed
by inﬂating the balloon of the catheter in order to measure air ﬂow
and pressure and hence resistance of collateral channels. The same
procedure was  repeated in the right upper lobe. The assessment
demonstrated that the upper lobes had integrity and no collateral
Open access under CC BY-NC-ND license.ﬂow was present with adjacent lobes (Fig. 2). A decision was made
to proceed with the insertion of endobronchial valves in the left
lower lobe. Two Zephyr® EBVs were placed in the left lower lobe:
one in the common lower lobe bronchus and the other in B6. The
 BY-NC-ND license.
CASE  REPORT  –  OPEN  ACCESS
286 J. Votruba et al. / International Journal of Surgery Case Reports 2 (2011) 285– 287
Fig. 1. Pre-procedure CT.
Fig. 2. Chartis ﬂow and index curve.
Fig. 3. CXR pre procedure andFig. 4. CT day 2 post procedure.
patient remained stable throughout this procedure. A similar pro-
cedure was  then performed on the right side, again in the common
lower lobe bronchus and B6.
A chest X-ray the following day showed signiﬁcant lung volume
reduction bilaterally with lessening of diaphragmatic ﬂattening and
no evidence of pneumothorax (Fig. 3). A CT scan on day 2 conﬁrmed
bilateral lung volume reduction and expansion of the healthier
upper lobes (Fig. 4). On the third post-operative day, the patient
was taken off the ventilator and did not require oxygen support. He
was discharged home on day 10 when he was  able to begin walking
slowly without the need for oxygen. Thirty days later, he showed
further improvement in his exercise tolerance and was using oxy-
gen only when undertaking exercise on an exercise bicycle. He had
not suffered any complications. His FEV1 had increased to 1.32L
(38% predicted) and RV reduced to 3.2L (142% predicted) (Table 1).
3. DiscussionEmphysema produces alveolar damage resulting in a reduced
surface area for gas exchange and loss of elastic recoil. Gas trap-
ping and hyperinﬂation of the disease lobe causes compression of
the adjacent lobe. The main risk factor for emphysema is tobacco
 day 1 post procedure.
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Table  1
Pulmonary function before and after Zephyr EBV placement.
Measurement Baseline litres (%
predicted)
30 days post
procedure litres (%
predicted)
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moking and typically this affects the upper lobes to a greater extent
han the lower.1,2 Alpha-1-antitrypsin deﬁciency is a rarer cause of
mphysema and by contrast typically affects the lower lobes. This
atient was somewhat unusual in that he had predominantly lower
obe disease although screening for alpha-1-antitrypsin deﬁciency
as negative.
The Zephyr endobronchial valve (Zephyr EBV®) is designed to
reate volume reduction of the diseased hyperinﬂated lobe. The
evice consists of a one-way, silicone, duckbill valve attached to a
ickel–titanium (Nitinol), self-expanding retainer that is covered
ith a silicone membrane. It is implanted in the target bronchus
sing a ﬂexible delivery catheter that is guided to the targeted
ronchus by inserting it through a 2.8 mm working channel of
 bronchoscope. It allows air and secretions to escape from the
ccluded lobe on expiration but prevents air from entering on
nspiration.3 This results in atelectasis of the target lobe, thereby
llowing re-expansion of the adjacent, less diseased lobe. In a
arge randomized controlled study, statistically signiﬁcant beneﬁt
as seen in the treatment group compared to the control group
f best medical care. A subgroup of patients obtained a much
reater response and suggested that targeting lobes to select those
ith least collateral ventilation would further improve clinical
esponse.4
The Chartis® Pulmonary Assessment System is a catheter-based
ystem that measures pressures and ﬂows during respiration and
alculates the resistance of the collateral channels.5 This enables
reatment to be planned such that lung areas with the lowest col-
ateral ﬂow can be targeted, optimizing the clinical effects gained
rom endobronchial valve therapy.6
This ventilator dependent patient had exhausted all medical
reatment options. Surgical options for emphysema include lung
olume reduction surgery (LVRS) or lung transplant in selected
ases. Surgical lung volume reduction therapy has been shown to
rovide clinical beneﬁt and also a marginal increase in the survival
n a subgroup of patients.7 However, it is associated with signiﬁ-
ant morbidity and mortality and it has not been widely used in
atients who are ventilator dependent. Lung transplant is another
urgical option but poor outcomes have been reported in patients
equiring pre-operative mechanical ventilation.8,9
In this case, by using Chartis® to plan the insertion of EBV, in
 patient with no other treatment options, signiﬁcant lung vol-
me  reduction was achieved with a reduction in RV of 29% and an
mpressive improvement in FEV1 of 48%. In order to give maximum
pportunity for an effective response in a severely compromised
atient, EBVs were placed bilaterally. Both the Chartis® assessment
nd the EBV insertion were able to be performed bronchoscopically
hrough the tracheostomy. After two months in an Intensive CarePEN  ACCESS
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Unit, the patient was able to be ventilator independent, leave hos-
pital and was  no longer dependent upon regular supplementary
oxygen. He was able to resume an independent life and exercise.
4. Conclusion
In this case, the use of Chartis® to plan EBV treatment resulted
not only in clinical beneﬁt but also in a health-economic beneﬁt
where a patient was  able to transition from ICU ventilator depen-
dency to an independent existence.
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